MarketPeel
Insider Trading Intelligence
BB

Blake Borgeson

RXRX
DIRECTOR · RECURSION PHARMACEUTICALS, INC. · CIK 0001856094
FILING MIX · LIFETIME25%/75%
BUYS
24
SELLS
73
TOTAL VALUE
$9.98M
COMPANIES
1
ACTIVE SINCE
Apr 2021
HOLDINGS NOW
6,258,287
AVG SELL PX
$6.34
TRADE KIND
SHOWING 97 / 97
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
67 backtested trades · 8 horizons · 29 pending
Forward-return performance of every backtestable P/S trade by Blake Borgeson, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d67+62.69%-1.02%+0.44%-1.46%-4.21%-0.82
14d67+65.67%-3.04%+0.64%-3.51%-7.58%-1.71
30d67+72.73%-4.68%+1.39%-6.07%-9.69%-2.13
60d67+71.21%-6.07%+2.63%-8.57%-14.02%-2.28
90d67(2 pending)+64.62%-6.88%+4.00%-11.01%-18.35%-2.41
180d67(5 pending)+58.06%-9.55%+8.11%-17.54%-20.86%-4.71
1y67(6 pending)+73.77%-15.91%+18.03%-33.94%-40.20%-9.49
2y67(16 pending)+94.12%-42.31%+40.14%-82.00%-89.74%-26.40
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RXRX · 6,258,287 shares · as of Jun 17, 2026
01,922,2733,844,5465,766,8187,689,09120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 24 buys / 73 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
88,4246,258,287Jun 17, 2026Jun 22, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
30,000$3.68$110.4K6,169,863Jun 2, 2026Jun 4, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
30,000$3.52$105.6K6,199,863May 5, 2026May 6, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
30,000$3.10$93.0K6,229,863Apr 7, 2026Apr 8, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
170,000$3.46$588.2K6,259,863Mar 3, 2026Mar 4, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
220,000$4.20$924.0K6,429,863Feb 3, 2026Feb 5, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
220,000$4.36$959.2K6,649,863Jan 6, 2026Jan 8, 2026View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
220,000$4.37$961.4K6,869,863Dec 2, 2025Dec 4, 2025View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
44,03144,031Jun 18, 2025Jun 23, 2025View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
22,0167,089,863Jun 18, 2025Jun 23, 2025View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,7347,067,847Jan 2, 2025Jan 6, 2025View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$7.64$87.5K7,066,113Nov 12, 2024Nov 14, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.72$76.9K7,077,560Oct 29, 2024Oct 31, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.67$76.3K7,089,007Oct 15, 2024Oct 17, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.22$71.1K7,098,428Oct 1, 2024Oct 3, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
2,0267,100,454Oct 1, 2024Oct 4, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.84$78.3K7,109,875Sep 17, 2024Sep 19, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.27$71.7K7,121,322Sep 3, 2024Sep 5, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$7.12$81.5K7,132,769Aug 20, 2024Aug 22, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.82$78.1K7,144,216Aug 6, 2024Aug 8, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$8.48$97.0K7,155,663Jul 23, 2024Jul 25, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$7.32$83.7K7,167,110Jul 9, 2024Jul 11, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,4417,178,557Jul 1, 2024Jul 3, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$9.51$108.8K7,177,116Jun 25, 2024Jun 27, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$8.45$96.8K7,188,563Jun 11, 2024Jun 13, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
13,0977,200,010Jun 3, 2024Jun 5, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
26,19326,193Jun 3, 2024Jun 5, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$9.17$104.9K7,186,913May 28, 2024May 30, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
20,054$10.12$202.9K7,198,360May 14, 2024May 16, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$7.95$91.0K7,218,414Apr 30, 2024May 2, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$7.66$87.7K7,229,861Apr 16, 2024Apr 18, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$8.82$100.9K7,241,308Apr 2, 2024Apr 3, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
20,054$10.79$216.4K7,252,755Mar 19, 2024Mar 21, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
20,054$12.06$241.8K7,272,809Mar 5, 2024Mar 6, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
309$13.04$4.0K7,292,863Feb 20, 2024Feb 21, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
19,745$12.31$243.1K7,293,172Feb 20, 2024Feb 21, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$9.30$106.5K7,312,917Feb 6, 2024Feb 8, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
20,054$10.58$212.1K7,324,364Jan 23, 2024Jan 25, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
13,751$13.81$189.9K7,344,418Jan 9, 2024Jan 11, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,303$13.21$83.3K7,358,169Jan 9, 2024Jan 11, 2024View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
20,054$10.63$213.1K7,364,472Dec 26, 2023Dec 28, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$7.40$84.7K7,384,526Dec 12, 2023Dec 14, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
11,447$6.72$76.9K7,395,973Nov 28, 2023Nov 30, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$6.32$56.2K7,407,420Nov 14, 2023Nov 16, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$5.27$46.9K7,416,305Oct 31, 2023Nov 2, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$6.58$58.5K7,425,190Oct 17, 2023Oct 19, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$7.29$64.8K7,434,075Oct 3, 2023Oct 5, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.36$74.3K7,442,960Sep 19, 2023Sep 21, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.79$78.1K7,451,845Sep 5, 2023Sep 7, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.91$79.2K7,460,730Aug 22, 2023Aug 24, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
3,272$11.75$38.4K7,469,615Aug 8, 2023Aug 10, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
14,498$11.03$159.8K7,472,887Aug 8, 2023Aug 10, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
18,719$14.61$273.5K7,487,385Jul 25, 2023Jul 27, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALEGRANT
Gift
14,0007,506,104Jun 29, 2023Jul 27, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$7.39$65.6K7,528,989Jun 27, 2023Jun 29, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,6127,537,874Jun 16, 2023Jun 21, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
25,22425,224Jun 16, 2023Jun 21, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
15,485$9.98$154.5K7,525,262Jun 13, 2023Jun 15, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.79$78.1K7,540,747May 30, 2023Jun 1, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$5.09$45.2K7,549,632May 16, 2023May 17, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$5.93$52.7K7,558,517Apr 18, 2023Apr 20, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$6.53$58.0K7,567,402Apr 4, 2023Apr 6, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$7.40$65.7K7,576,287Mar 21, 2023Mar 23, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.33$74.0K7,585,172Mar 7, 2023Mar 9, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$7.73$68.7K7,594,057Feb 21, 2023Feb 23, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.81$78.3K7,602,942Feb 7, 2023Feb 9, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.71$77.4K7,611,827Jan 24, 2023Jan 26, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$7.69$68.3K7,620,712Jan 10, 2023Jan 12, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,3257,629,597Jan 3, 2023Jan 5, 2023View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$7.25$64.4K7,628,272Dec 27, 2022Dec 29, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.96$79.6K7,637,157Dec 13, 2022Dec 15, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
8,885$8.75$77.8K7,646,042Nov 29, 2022Dec 1, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
17,770$11.12$197.6K7,654,927Nov 16, 2022Nov 18, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
9207,672,697Oct 3, 2022Oct 5, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,1867,671,777Jul 1, 2022Jul 6, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
18,1457,670,591Jun 14, 2022Jun 16, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
36,29036,290Jun 14, 2022Jun 16, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
1,3007,652,446Apr 1, 2022Apr 5, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
9,625$18.03$173.5K7,651,146Jan 4, 2022Jan 5, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
5557,660,771Jan 3, 2022Jan 5, 2022View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
9,625$18.75$180.5K7,660,216Dec 21, 2021Dec 23, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
7,725$20.38$157.5K7,670,241Dec 7, 2021Dec 9, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
400$21.03$8.4K7,669,841Dec 7, 2021Dec 9, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
1,500$19.78$29.7K7,677,966Dec 7, 2021Dec 9, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
7,725$19.05$147.2K7,679,466Nov 18, 2021Nov 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
1,900$18.32$34.8K7,687,191Nov 18, 2021Nov 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4577,689,091Oct 1, 2021Oct 5, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
2787,688,634Jul 1, 2021Jul 6, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASE
12,50012,500Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
12,5000Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
7,688,3560Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
378,3090Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASE
7,688,3567,688,356Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASE
923,0527,688,356Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE
544,7430Apr 20, 2021Apr 22, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
6,2506,765,304Apr 16, 2021Apr 19, 2021View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
12,50012,500Apr 15, 2021Apr 19, 2021View →
Other insiders · RXRX
Loading peer insiders…
About this filer
CIK 0001856094
ROLE
Director
PRIMARY
RXRX
COMPANIES
1
ACTIVE SINCE
Apr 2021
MARKETPEEL · /INSIDER/0001856094DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback